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Randomized clinical trials are regarded as the highest level of evidence for informing clinical 
guidelines and clinical practice.1,2 The robustness of conduct and reporting of the results of 
randomized clinical trials is therefore of primary importance. To improve the transparency and quality 
of reporting of clinical trials, the International Committee of Medical Journal Editors (ICMJE) 
endorsed a policy on mandatory registration of clinical trials, which came into effect in July 20053. 
The trial registration recommendations outlined by the ICMJE state that a trial must be registered in a 
publicly accessible registry, before the enrolment of the first study participants, in order to be 
considered for publication. This policy is designed to reduce publication bias, prevent selective 
reporting of desirable or non-reporting of undesirable results, and reduce research waste by making 
the research community aware of what questions are already being addressed by active trials. 
 
Previous studies have suggested that although ICMJE guidance recommends that journals should not 
publish manuscripts from trials that were not registered or were retrospectively registered, such trials 
continue to be published in the medical literature, including in high-impact journals.4 While 
compliance with ICMJE registration has been investigated in individual specialities such as 
cardiology5,6, no studies to date have reported on adherence to the ICMJE policy within respiratory 
medicine.  
 
This review was conducted in order to evaluate the registration practices of clinical trials published in 
high-impact respiratory medical journals from 2010-2018. Our aim was to determine the frequency of 
publication of unregistered and retrospectively registered trials and to determine temporal trends in 
publication practices.  
 
We conducted a systematic review based on the recommendations set in the PRISMA 
statement{ADDIN CSL_CITATION {"citationItems":[{"id":"ITEM-
1","itemData":{"DOI":"10.1136/BMJ.B2535","ISSN":"1756-
1833","PMID":"19622551","abstract":"David Moher and colleagues introduce PRISMA, an update of 
the QUOROM guidelines for reporting systematic reviews and meta-analyses\n\nSystematic reviews 
and meta-analyses have become increasingly important in health care. Clinicians read them to keep up 
to date with their specialty,1 2 and they are often used as a starting point for developing clinical 
practice guidelines. Granting agencies may require a systematic review to ensure there is justification 
for further research,3 and some medical journals are moving in this direction.4 As with all research, 
the value of a systematic review depends on what was done, what was found, and the clarity of 
reporting. As with other publications, the reporting quality of systematic reviews varies, limiting 
readers’ ability to assess the strengths and weaknesses of those reviews.\n\nSeveral early studies 
evaluated the quality of review reports. In 1987 Mulrow examined 50 review articles published in 
four leading medical journals in 1985 and 1986 and found that none met all eight explicit scientific 
criteria, such as a quality assessment of included studies.5 In 1987 Sacks and colleagues evaluated the 
adequacy of reporting of 83 meta-analyses on 23 characteristics in six domains.6 Reporting was 
generally poor; between one and 14 characteristics were adequately reported (mean 7.7, standard 
deviation 2.7). A 1996 update of this study found little improvement.7\n\nIn 1996, to address the 
suboptimal reporting of meta-analyses, an international group developed a guidance called the 
QUOROM statement (QUality Of Reporting Of Meta-analyses), which focused on the reporting of 
meta-analyses of randomised controlled trials.8 In this article, we summarise a revision of these 
guidelines, renamed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-
Analyses), which have been updated to address several conceptual and practical advances in the 
science of systematic reviews (see box).\n\n#### Conceptual issues in the evolution from QUOROM 
to PRISMA\n\n##### Completing a systematic review is an iterative process\n\nThe conduct of a 
systematic …","author":[{"dropping-particle":"","family":"Moher","given":"David","non-dropping-
particle":"","parse-names":false,"suffix":""},{"dropping-
particle":"","family":"Liberati","given":"Alessandro","non-dropping-particle":"","parse-
names":false,"suffix":""},{"dropping-particle":"","family":"Tetzlaff","given":"Jennifer","non-
dropping-particle":"","parse-names":false,"suffix":""},{"dropping-
particle":"","family":"Altman","given":"Douglas G","non-dropping-particle":"","parse-
names":false,"suffix":""},{"dropping-particle":"","family":"PRISMA Group","given":"","non-
dropping-particle":"","parse-names":false,"suffix":""}],"container-title":"BMJ (Clinical research 
ed.)","id":"ITEM-1","issued":{"date-parts":[["2009","7"]]},"page":"b2535","publisher":"British 
Medical Journal Publishing Group","title":"Preferred reporting items for systematic reviews and 
meta-analyses: the PRISMA statement.","type":"article-
journal","volume":"339"},"uris":["http://www.mendeley.com/documents/?uuid=cd8f695a-17fe-3164-
b8b9-073773a7311b","http://www.mendeley.com/documents/?uuid=dbbfafdb-09fa-4aff-8689-
cab5e163f887"]}],"mendeley":{"formattedCitation":"<sup>7</sup>","plainTextFormattedCitation":"
7","previouslyFormattedCitation":"<sup>7</sup>"},"properties":{"noteIndex":0},"schema":"https://g
ithub.com/citation-style-language/schema/raw/master/csl-citation.json"}}. This review was 
prospectively registered at PROSPERO (CRD42018102819). 
 
All searches were conducted using PubMed, as all publications included are PubMed-indexed. We 
used the sensitivity- and precision-maximizing version of The Cochrane search strategy8. Publication 
date was set between January 2010 and July 2018. 2010 was chosen since mandatory trial registration 
was introduced in 2005, and therefore we considered that by 2010 the majority of published trials 
would be eligible for registration. We studied published articles within 8 journals; The Lancet 
Respiratory Medicine, American Journal of Respiratory and Critical Care medicine, Thorax, 
European Respiratory Journal, Chest, Respiratory Research, Respirology and Annals of the American 
Thoracic Society. These journals were chosen on the basis of impact factor, publication of original 
research including clinical trials and publication across all sub-specialities within respiratory 
medicine.  
 
No language restrictions were applied. All articles identified by search were reviewed by title and 
abstract, and the full text of the publication was reviewed if potentially relevant. We used the ICMJE 
definition of a clinical trial to determine study inclusion9. We excluded studies that reported on post-
hoc analyses or secondary analyses based on trial datasets. This study was conducted by four 
reviewers, two of which were involved in both data extraction and analysis and two were involved in 
the data extraction step only. Discrepancies were resolved by discussion. 
 
The following data were extracted for each study; publication title, whether or not the trial was a 
multi-centre study, region, registration number, date of enrolment of first patient, date of registration, 
funding source, whether the trial was academic or commercial based on the funding source, year of 
publication, and outcome of the trial.  
 
Classification of trials followed a published approach used by the British Medical Journal.4 Briefly, a 
trial was considered to be registered if the publication included a registration number of an acceptable 
primary registry – one belonging to the WHO International Clinical Trials Registry Platform 
(ICTRP). If no registration number was reported in the publication, the trial was searched for using 
the ICTRP search platform. If no registration number was found or the trial was registered in a WHO 
non-compliant registry, the trial was considered ‘not registered’.  
 
The study start date, which the ICMJE defines as the date of enrolment of first patient9, was recorded 
as that reported in the publication. The outcome of each trial was recorded as either ‘positive’ or 
‘negative’ depending on whether or not the primary outcome measure of the trial reached statistical 
significance.  
 
Trials included for further analysis were defined by their registration status as ‘prospective’ 
(registration before or on the day of enrolment of first patient), ‘retrospective’ (registration after the 
day of first patient enrolment) or ‘not registered’. Retrospectively registered trials were further 
divided into subclasses according to the time delay (in months) between the date of enrolment of first 
participant and date of registration. 
 
We calculated simple proportions to describe the frequency of registered and non-registered trials. 
Logistic regression was used to identify factors associated with trial registration status. P<0.05 was 
considered statistically significant.  
 
The search strategy identified a total of 2109 records, of which 1108 were excluded by abstract as 
they did not fulfil the criteria for a clinical trial. Of the 1082 potentially eligible trials, a further 158 
were excluded as they did not meet the full inclusion criteria – these were mainly publications which 
did not report the primary results of a trial. A total of 925 studies were included for further analysis. 
Some publications presented the primary results of two or more trials – most of these were 
combinations of two identical trials due to regulatory requirements – and accounting for these, the 
number of trials included was 955. These studies of multiple trials were included as single entries for 
our analyses.  
 
Of the 925 studies included for our analyses, 57.1% were multi-centre trials. The majority (64.2%) of 
trials reported a positive outcome.  
 
Overall, 47.7% of trials were prospectively registered, and 42.2% were regarded as retrospectively 
registered. A total of 10.2% of trials were not registered. Excluding trials that started before 
mandatory registration was introduced in 2005, 51.5% were prospectively registered, 39.0% were 
retrospectively registered and 9.5% were not registered. Examining publications by journal, the 
Lancet Respiratory Medicine had the highest percentage of prospectively registered trials (68.5%) and 
Respirology the lowest (32.4%) across the 8-year study period (Figure 1B). Commercially funded 
studies were more likely to be prospectively registered than academically funded studies (p=0.003, 
figure 1C). The proportion of retrospectively and non-registered studies decreased progressively from 
2010 to 2018 from a mean of 72.4% in 2010 to 35.6% of trials in 2018 (figure 1D). Non-registered 
studies accounted for 24.6% of published studies in 2010 but were virtually eliminated by 2018 (0.4% 
of published studies, figure 1E). In Figure 1F, we show the publication factors associated with non-
prospective trial publication. There was a significant effect of region (p=0.004), and date of 
publication (p=0.008) with failure to prospectively register trials being most common in Spain (OR 
6.5 95% CI 2.65-15.8), followed by South America, Italy and China. Australia and New Zealand had 
the lowest odds of retrospective registration (OR 0.52 95% CI 0.27-1.01). Single-centre studies were 
more likely to be retrospectively or non-registered (OR 2.14 95% CI 1.48-3.10). Trials in cystic 
fibrosis (71.1%), Pulmonary vascular disease (70.4%), interstitial lung disease (61.5%) and asthma 
(59.1%) were most likely to be prospectively registered. Studies in Sleep medicine (35.7% and cancer 
(47.6%) were least likely to be registered prospectively. 
Retrospective trial registration was frequently just within 1 month of study start (29% of trials) but a 
total of 38.6% of all trials were registered >12 months after the first participant was enrolled (Figure 
1G). These trials at higher risk of bias, which are registered more than 1 year after study start date, 
also decreased rapidly in numbers over time (figure 1H). 
 
To evaluate the potential for registration status to bias the literature, we examined whether registration 
status impacted the likelihood of a positive result. Compared to prospectively registered studies, 
unregistered studies were 80% more likely to have a positive result (OR 1.80 95% CI 1.10-2.95, 
p=0.02). Retrospectively registered studies were 33% more likely to be positive (OR 1.33 95% CI 
1.01-1.77, p=0.04). 
 
Therefore In this review of clinical trials published between 2010 and present in eight high-impact 
respiratory medical journals, we found that a significant proportion of clinical trials remains 
retrospectively registered, years after the ICMJE introduced their policy on mandatory prospective 
trial registration. Additionally, we have shown that there is still a substantial number of trials which 
are not registered. Our results are in line with previous reports on trial registration practices in the 
post-implementation period of the ICMJE policy10. We observed a trend towards better registration 
compliance from 2010 to 2018, which was expected, and resonates with previous findings on the 
improvements seen over the years in clinical trial registration11. 
 
There is evidence that most retrospective registration may be inadvertent.12 Some investigators may 
not be aware that their trial meets the criteria for a trial which should be registered. Some 
investigators may be completely unaware of registration policies, although thirteen years post-
implementation of the ICMJE policy this is increasingly difficult to justify.12 Nevertheless one of the 
main purposes of mandatory prospective registration is to prevent selective reporting of trial 
outcomes. Our finding that retrospectively registered trials are more likely to be positive has two 
possible explanations, either researchers may register their trial retrospectively in order to engage in 
selective reporting of their results or editors are more likely to ignore requirement for prospective 
registration in the face of a positive trial.13 It is therefore important that investigators, journal editors 
and members of research or funding organisations are all involved in addressing this issue. There is a 
responsibility on journals to adequately check registration status at the time of submission.13 There is 
evidence for the majority of retrospectively registered studies being registered before submission to a 
journal10, and thus these inappropriately registered trials may go on to be published if there are no 
strict quality checks on the trial’s registration status. 
 
Commercially funded trials were more often registered prospectively, which may reflect more strict 
regulation imposed on studies with commercial interest. Studies from certain countries including 
Spain, South America, Italy and China, and single-centre studies in general, were more likely to be 
registered inappropriately. This may be explained by variation in regional registration policies and the 
availability of resources for project management11. 
 
The quality of registration reporting has been reported in detail elsewhere14,15, but we also found 
inconsistencies and lack of clarity in trial reporting including failure to provide study dates in 
publications. We may therefore underestimate the scale of retrospective registration since we were 
conservative in our assessment of registration status. 
 
In conclusion, adherence to clinical trial registration policies in respiratory medicine is improving 
rapidly. Publication of non-registered trials has been virtually eliminated and the challenge now is to 
encourage compliance with prospective registration among investigators and editors.  
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Figure 1. Systematic review of clinical trial registration in respiratory medicine journals 2010-2018. 
A: Flow chart for identification of clinical trials, B: clinical trial registration status by journal 2010-
2018, data presented as percentages of published trials, C: registration status stratified by funding 
status, D: retrospective and non-registered studies by journal over time, E: % of non-registered trials 
over time. F: Forest plot showing the results of the logistic regression analysis for risk of retrospective 
or non-registered trials. Data are shown as odds ratios with 95% CI. The upper 95% CI have been 
limited to 10 to allow easier visualisation of the overall data. G: Timing of retrospective trial 
registration. H: Proportion of trials registered greater than 1 year after study start date over time in all 
8 journals. 
Abbreviations: LRM = Lancet Respiratory Medicine, AJRCCM = American Journal of Respiratory 
and Critical Care Medicine, ERJ = European Respiratory Journal, Resp Res = Respiratory Research, 
Ann ATS = Annals of the American Thoracic Society.  
 
